You have 9 free searches left this month | for more free features.

Pembrolizumab

Showing 1 - 25 of 1,381

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Glioblastoma, Adult Trial in Cleveland (Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days

Recruiting
  • Glioblastoma, Adult
  • Pembrolizumab at 7 days prior
  • +3 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Mar 10, 2022

Biliary Tract Cancer Trial in Goyang-si, Seoul (SMT-NK inj.+Pembrolizumab, Pembrolizumab)

Recruiting
  • Biliary Tract Cancer
  • SMT-NK inj.+Pembrolizumab
  • Pembrolizumab
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • +2 more
Jun 28, 2022

Thyroid Trial in Houston (Pembrolizumab)

Recruiting
  • Thyroid
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Triple Negative Breast Cancer Trial in Shanghai (Cisplatin, Nab-paclitaxel, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 18, 2022

Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Apr 25, 2022

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
May 26, 2022

Tumors Trial (vibostolimab, pembrolizumab, pemetrexed)

Active, not recruiting
  • Neoplasms
  • vibostolimab
  • +6 more
  • (no location specified)
Apr 22, 2022

Gastric Cancer Trial in Seoul (Pembrolizumab)

Recruiting
  • Gastric Cancer
  • Pembrolizumab
  • Seoul, Korea, Republic of
    Samsung Medical Center
Dec 23, 2021

Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)

Not yet recruiting
  • Muscle Invasive Bladder Carcinoma
  • +2 more
  • Pembrolizumab
  • (no location specified)
Jun 23, 2022

Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)

Not yet recruiting
  • Prostate Cancer Metastatic
  • Pembrolizumab
  • +2 more
  • (no location specified)
Sep 29, 2022

Melanoma Trial (Dapansutrile, Pembrolizumab)

Not yet recruiting
  • Melanoma
  • (no location specified)
Jul 26, 2022

Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
Jun 28, 2022

Colorectal Cancer Trial (Pembrolizumab)

Not yet recruiting
  • Colorectal Cancer
  • Pembrolizumab
  • (no location specified)
Apr 13, 2022

Tumors Trial (Favezelimab, Pembrolizumab, Oxaliplatin)

Active, not recruiting
  • Neoplasms
  • Favezelimab
  • +7 more
  • (no location specified)
Apr 11, 2022

Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Mucosal Melanoma
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Sep 15, 2022

Hepatocellular Carcinoma Trial (Pembrolizumab)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • (no location specified)
Jun 30, 2022

Advanced Kidney Cancer Trial in Tianjin (Pembrolizumab plus Lenvatinib)

Recruiting
  • Advanced Kidney Cancer
  • Pembrolizumab plus Lenvatinib
  • Tianjin, Tianjin, China
    Changyi Quan
Aug 4, 2022

Renal Cell Cancer Trial (Axitinib, Pembrolizumab)

Withdrawn
  • Renal Cell Cancer
  • (no location specified)
Jul 29, 2022

Locally Advanced Esophageal and Gastric Cancers (EGC) Trial in Durham (Pembrolizumab)

Recruiting
  • Locally Advanced Esophageal and Gastric Cancers (EGC)
  • Pembrolizumab
  • Durham, North Carolina
    Duke Cancer Center
Mar 23, 2022

Carcinoma, Hepatocellular Trial in Shanghai (Pembrolizumab+Lenvatinib)

Not yet recruiting
  • Carcinoma, Hepatocellular
  • Shanghai, Shanghai, China
    Zhongshan hospital
May 24, 2022

Advanced Solid Cancers Trial in Tainan (ADI PEG20, Pembrolizumab)

Terminated
  • Advanced Solid Cancers
  • ADI PEG20
  • Pembrolizumab
  • Tainan, Taiwan
    Facility National Cheng Kung University
Apr 20, 2022

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial (radiation, biological, procedure)

Withdrawn
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
  • Copper Cu 64-DOTA-pembrolizumab
  • +2 more
  • (no location specified)
Jun 7, 2022

Pancreatic Cancer Trial in Lexington (Cabozantinib, Pembrolizumab)

Recruiting
  • Pancreatic Cancer
  • Lexington, Kentucky
    University of Kentucky Markey Cancer Center
Feb 26, 2022

NSCLC Trial (Pembrolizumab, Docetaxel)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022